Evaluating the risk of pneumonia with inhaled corticosteroids in COPD: Retrospective database studies have their limitations SA

Respiratory Medicine

Volumn 123, Issue , 2017, Pages 94-97

  Bourbeau, J ^a   Aaron, S D ^b   Barnes, N C ^c   Davis, K J ^d   Lacasse, Y ^e   Nadeau, G ^f  

^a RESEARCH INSTITUTE OF THE MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

^c GLAXOSMITHKLINE   (United Kingdom)

^d GLAXOSMITHKLINE   (United States)

^e LAVAL UNIVERSITY   (Canada)

^f GLAXOSMITHKLINE   (Canada)

Author keywords

COPD; Health administrative database study; Inhaled corticosteroids; Retrospective study; Risk of pneumonia

Indexed keywords

BUDESONIDE; FLUTICASONE PROPIONATE; GLUCOCORTICOID;

AMBULATORY CARE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DATA BASE; HOSPITALIZATION; HUMAN; INFECTION RISK; MORTALITY; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PNEUMONIA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVIEW; RISK FACTOR; CHEMICALLY INDUCED; FACTUAL DATABASE; INHALATIONAL DRUG ADMINISTRATION; METHODOLOGY; ONTARIO; PROCEDURES; QUEBEC; RISK ASSESSMENT;

ADMINISTRATION, INHALATION; DATABASES, FACTUAL; GLUCOCORTICOIDS; HUMANS; ONTARIO; PNEUMONIA; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUEBEC; RESEARCH DESIGN; RETROSPECTIVE STUDIES; RISK ASSESSMENT;

EID: 85007467249     PISSN: 09546111     EISSN: 15323064     Source Type: Journal    
DOI: 10.1016/j.rmed.2016.12.015     Document Type: Review

References (24)

1. [1] Evans, J., Chen, Y., Pat, G., Cam, P.G., et al. Estimating the prevalence of COPD in Canada: reported diagnosis versus measured airflow obstruction. Res. Article Health Rep. 25:3 (March 2014), 3–11 Statistics Canada, Catalogue no. 82-003-X.
2. [2] Buist, A., McBurnie, M., Vollmer, W., et al. International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. Lancet 370 (2007), 741–750.
3. [3] Hill, K., Goldstein, R.S., Guyatt, G.H., et al. Prevalence and underdiagnosis of chronic obstructive pulmonary disease among patients at risk in primary care. Can. Med. Assoc. J. 182 (2010), 673–678.
4. [4] Statistics Canada, Canadian Community Health Survey—annual Component. Available at: http://www23.statcan.gc.ca/imdb/p2SV.pl?Function=getSurvey&SDDS=3226&Item_Id=118913.
5. [5] Gershon, A.S., Guan, J., Victor, J.C., Goldstein, R., To, T., Quantifying health services use for chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 187 (2013), 596–601.
6. [6] O'Donnell, D.E., Aaron, S., Bourbeau, J., Hernandez, P., Marciniuk, D.D., Balter, M., et al. Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease - 2007 update. Can. Respir. J. 14:Suppl B (2007), 5B–32B change to 2008 vol. 15.
7. [7] Criner, G.J., Bourbeau, J., Diekemper, R.L., et al. Prevention of acute exacerbations of chronic obstructive pulmonary disease: American college of chest physicians and canadian thoracic society. Chest 47:4 (2015), 894–942.
8. [8] Muellerova, H., The natural history of community-acquired pneumonia in COPD patients: a population database analysis. Resp. Med. 106 (2012), 1124–1133.
9. [9] Kew, K.M., Seniukovich, A., Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease. Cochrane Database Syst. Rev., 3, 2014, CD010115.
10. [10] Chen, D., Restrepo, M.I., Fine, M.J., Pugh, M.J., Anzueto, A., Metersky, M.L., Nakashima, B., Good, C., Mortensen, E.M., Observational study of inhaled corticosteroids on outcomes for COPD patients with pneumonia. Am. J. Respir. Crit. Care Med. 184 (1-8-2011), 312–316.
11. [11] DiSantostephano, R.L., Sampson, T., Van le, H., et al. Risk of pneumonia with inhaed corticosteroid versus long-acting bronchodilator regimens in Chronic Obstructive Pulmonary Disease: a new user cohort study. PLoS One, 9, 2014, e97149.
12. [12] Dransfield, M.T., Bourbeau, J., Jones, P., et al. Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only in the prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomized controlled trials. Lancet Respir. 1 (2013), 210–223.
13. [13] Vestbo, J., Anderson, J.A., Brook, R.D., et al. Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomized controlled trial. Lancet. 387 (2016), 1817–1826.
14. [14] Vestbo, J., Anderson, J., Brook, R.D., et al. Study to understand mortality and morbidity in COPD (SUMMIT). Eur. Respir. J., 46(59), 2015.
15. [15] Burns, P.B., Rohrich, R.J., Chung, K., The levels of evidence and their role in evidence-based medicine. Plast. Reconstr. Surg. 128:1 (2011), 305–310.
16. [16] Gershon, A.S., Campitelli, M.A., Croxford, R., Stanbrook, M.B., To, T., Upshur, R., Stephenson, A.L., Stukel, T.A., Combination long-acting β-agonists and inhaled corticosteroids compared with long-acting β-agonists alone in older adults with chronic obstructive pulmonary disease. JAMA 312:11 (2014 Sep 17), 1114–1121.
17. [17] Suissa, S., Patenaude, V., Lapi, F., Ernst, P., Inhaled corticosteroids in COPD and the risk of serious pneumonia. Thorax 68 (2013), 1029–1036.
18. [18] Lacasse, Y., Montori, V.M., Lanthier, C., Maltais, F., The validity of diagnosed chronic obstructive pulmonary disease from a large database. Can. Resp. J. 12 (2005), 251–256.
19. [19] reportData on File: RAMQ Report 2010.
20. [20] Hargreave, F., Dolovich, J., Newhouse, M., The Assessment and treatment of asthma: a conference report. JACI 85 (1990), 1098–1111.
21. [21] Suissa, S., Letter to the editor. JAMA, 313, 2015, 305.
22. [22] Data on file: IMS report (CompuScript December 2005).
23. [23] Torres, A., Peetermans, W.E., Viegi, G., et al. Risk factors for community-acquired pneumonia in adults in Europe: a literature review. Thorax 68 (2013), 1057–1065.
24. [24] Hernandez, P., Balter, M., Chan, C., et al. Canadian practice assessment in chronic obstructive pulmonary disease: respiratory specialist physician perception versus patient reality. Can. Respir. J. 20 (2013), 97–105.